ERG7 Antibody

Basic Research Questions

• What is ERG7 and why is it important in biochemical research?

ERG7 (lanosterol synthase) is an enzyme encoded by the ERG7 gene that converts oxidosqualene to lanosterol, the first cyclic component in the sterol biosynthesis pathway. This enzyme is critical for ergosterol synthesis in fungi, making it an important target for antifungal drug development.

In yeast, ERG7p is almost exclusively associated with lipid particles, as demonstrated through enzymatic activity assays, Western blot analysis, and in vivo localization studies using ERG7p-GFP constructs . This localization is significant because the enzyme's substrate, oxidosqualene, also accumulates predominantly in lipid particles in erg7 deletion strains or in wild-type cells treated with oxidosqualene cyclase inhibitors .

Notably, ERG7 has important protein-protein interactions within the ergosterol biosynthesis pathway, particularly with the 3-ketoreductase enzyme (ERG27p). Research has demonstrated that ERG27p is required not only for its own catalytic function but also for the proper functioning of ERG7p, suggesting a chaperone-like activity .

• How can I validate the specificity of an ERG7 antibody for research applications?

Validating ERG7 antibody specificity requires a systematic approach similar to established antibody validation protocols:

Recommended validation workflow:

• Generate knockout controls: Create ERG7 knockout cell lines using CRISPR/Cas9 gene editing. Design guide RNAs targeting the ERG7 gene and verify knockouts by sequencing .

• Perform comparative immunoblotting: Test the antibody by Western blot comparing wild-type and knockout cells. A specific antibody will show a band of the expected size (~83 kDa) in wild-type cells that is absent in knockout cells .

• Conduct cross-application testing: Validate the antibody across multiple applications (immunoprecipitation, immunofluorescence) using the same knockout controls .

• Perform peptide competition assays: Pre-incubate the antibody with an excess of the immunizing peptide before application to confirm epitope specificity .

• What experimental conditions should be optimized when using ERG7 antibodies for Western blotting?

When using ERG7 antibodies for Western blotting, several parameters should be optimized:

Sample preparation:

• Extract proteins using a buffer containing detergents capable of solubilizing membrane-associated proteins (ERG7p is primarily associated with lipid particles) .

• For yeast samples, use glass bead lysis in a buffer containing 0.1M potassium phosphate (pH 7.4) .

• Include protease inhibitors to prevent degradation.

Gel electrophoresis and transfer:

• Use gradient gels (5-16%) for better resolution of the ~83 kDa ERG7 protein .

• Transfer to nitrocellulose membranes, which may provide better signal-to-noise ratio for this protein.

Antibody incubation:

• Block with 5% BSA in TBST rather than milk, which may contain phosphatases that affect detection .

• Incubate primary antibody overnight at 4°C for optimal binding.

• For quantitative immunoblotting, use a total protein stain (like REVERT) to normalize loading rather than relying on single housekeeping proteins .

Detection:

• Both chemiluminescence and infrared fluorescence detection systems can be used, with the latter offering better quantitative capacity .

• What cell or tissue types are most appropriate for studying ERG7 expression?

The choice of experimental system for studying ERG7 depends on your research focus:

For fungal ERG7 studies:

• Saccharomyces cerevisiae is the standard model organism, with well-characterized ERG7 function and available genetic tools .

• Candida albicans is relevant for pathogenesis studies, as ergosterol synthesis is critical for virulence and antifungal resistance .

For mammalian ortholog studies:

• The mammalian ortholog of yeast ERG7 is also called lanosterol synthase (LSS).

• HepG2 (liver) cells express relatively high levels of LSS and are suitable for studies of cholesterol biosynthesis.

Selection approach:

• Use proteomic databases like PaxDB to identify cell lines with high expression levels of your target protein .

• Validate expression using quantitative immunoblotting across multiple cell lines before selecting your experimental system .

Advanced Research Questions

• How can I design experiments to study ERG7-ERG27 protein interactions using antibodies?

The interaction between ERG7p and ERG27p represents an important model for studying protein-protein interactions in metabolic pathways. Here's a comprehensive experimental approach:

Co-immunoprecipitation strategy:

• Prepare cell lysates in a gentle lysis buffer (e.g., HEPES buffer with 1% digitonin) to preserve protein-protein interactions .

• Perform reciprocal co-IPs using anti-ERG7 and anti-ERG27 antibodies coupled to Protein A/G Sepharose .

• Analyze immunoprecipitated complexes by immunoblotting with antibodies against both proteins.

• Include appropriate controls: IgG control, input sample, and knockout cell lines for both proteins.

Site-directed mutagenesis approach:

• Create point mutations in ERG27 based on the known catalytic residues (Y202F, K206A) and other regions predicted to be involved in protein-protein interactions .

• Express these mutants in erg27 deletion strains.

• Assess both ERG27p catalytic activity and ERG7p activity to distinguish between effects on catalysis versus protein interaction .

• Perform co-IP experiments with the mutants to map interaction domains.

Notable finding from published research:
Mutations of the catalytic residues Y202F and K206A in ERG27p resulted in the accumulation of 3-ketosterones rather than oxidosqualenes, suggesting retention of ERG7p activity despite loss of ERG27p catalytic function . This important result demonstrates that the chaperone-like function of ERG27p toward ERG7p can be separated from its catalytic activity.

• What approaches can be used to investigate whether ERG7 forms homodimers or heterodimers in its native state?

Investigating ERG7's oligomeric state requires multiple complementary approaches:

Chemical cross-linking analysis:

• Treat intact cells or isolated organelles with membrane-permeable cross-linkers like EGS (ethylene glycolbis(succinimidylsuccinate)) .

• Analyze cross-linked products by SDS-PAGE and immunoblotting with ERG7 antibodies.

• The appearance of higher molecular weight bands would suggest oligomerization.

Size exclusion chromatography with antibody detection:

• Solubilize membranes or lipid particles under native conditions.

• Separate proteins by size exclusion chromatography.

• Analyze fractions by immunoblotting with ERG7 antibodies.

• Compare elution profiles with known molecular weight standards.

Fluorescence resonance energy transfer (FRET):

• Create fluorescently tagged ERG7 constructs (e.g., ERG7-CFP and ERG7-YFP).

• Express in appropriate cells and measure FRET signals.

• Positive FRET signals would indicate proximity consistent with dimerization.

Native PAGE with antibody detection:

• Solubilize samples under non-denaturing conditions.

• Separate by native PAGE.

• Perform immunoblotting with ERG7 antibodies.

• Higher molecular weight species compared to the calculated monomer would suggest oligomerization.

Research on the related enzyme ERG27p has demonstrated that it belongs to the short-chain dehydrogenase/reductase (SDR) family and may form homo- or heterodimers . Given the functional interaction between ERG7p and ERG27p, investigating potential heterodimer formation between these proteins would be particularly interesting.

• How can I use ERG7 antibodies to study the subcellular localization of lanosterol synthase in relation to the sterol biosynthetic pathway?

Studying ERG7's subcellular localization requires careful experimental design and appropriate controls:

Immunofluorescence microscopy protocol:

• Fix cells using either 4% paraformaldehyde (for membrane preservation) or cold methanol (for better antigen accessibility) .

• Permeabilize with 0.3% Triton X-100 in TBS with 5% BSA .

• Incubate with validated anti-ERG7 antibody (typically 2 μg/ml) overnight at 4°C .

• Use appropriate fluorophore-conjugated secondary antibodies and counterstain with DAPI.

Co-localization studies:

• Include markers for relevant organelles:

  • Lipid particles (e.g., BODIPY or Nile Red staining)

  • Endoplasmic reticulum (e.g., anti-Kar2/BiP)

  • Mitochondria (e.g., MitoTracker)

• Use confocal microscopy for precise co-localization analysis.

Validation controls:

• Include ERG7 knockout cells as negative controls.

• Use mosaic cultures of wild-type and knockout cells on the same coverslip for direct comparison .

• Include a secondary antibody-only control.

Advanced approaches:

• Combine with proximity ligation assay (PLA) to detect interactions with other ergosterol pathway enzymes in situ.

• Use super-resolution microscopy techniques for more precise localization.

Current research indicates that in yeast, ERG7p is almost exclusively associated with lipid particles, with negligible presence in other organelles including the endoplasmic reticulum . This is significant because many other enzymes in the ergosterol biosynthetic pathway are located in the ER, suggesting spatial organization of the pathway across multiple cellular compartments.

• What methods can be used to accurately quantify ERG7 protein levels across different experimental conditions?

Accurate quantification of ERG7 protein levels requires appropriate methodologies and controls:

Quantitative immunoblotting:

• Use a validated ERG7 antibody that shows linear signal response.

• Include a loading control strategy:

  • Total protein normalization using stains like REVERT is preferred over single housekeeping proteins .

  • Use the LI-COR Odyssey system or similar for direct fluorescence quantification .

• Include a standard curve of recombinant protein for absolute quantification.

ELISA-based quantification:

• Develop a sandwich ELISA using two antibodies recognizing different ERG7 epitopes.

• Create a standard curve using purified recombinant ERG7.

• Validate the assay for linearity, sensitivity, and specificity.

Mass spectrometry-based approaches:

• Use stable isotope-labeled internal standards (AQUA peptides) corresponding to unique ERG7 tryptic peptides.

• Process samples using standard proteomics workflows.

• Quantify ERG7 using targeted mass spectrometry (PRM or SRM).

Flow cytometry for single-cell analysis:

• Optimize cell fixation and permeabilization conditions.

• Stain with fluorophore-conjugated ERG7 antibodies.

• Include appropriate isotype controls.

• Use ERG7 knockout cells as negative controls.

• How can I troubleshoot cross-reactivity issues when using ERG7 antibodies in complex biological samples?

Cross-reactivity is a common challenge with antibodies, especially when studying conserved proteins like ERG7. Here's a systematic troubleshooting approach:

Diagnostic steps:

• Confirm with knockout controls: Always compare signals between wild-type and ERG7 knockout samples to identify non-specific bands .

• Test multiple antibodies: Use antibodies targeting different ERG7 epitopes to confirm findings.

• Assess species cross-reactivity: If working across species, determine if the observed cross-reactivity is due to recognition of homologous proteins.

Mitigation strategies:

• Optimize blocking conditions: Test different blocking agents (BSA, milk, commercial blockers) and concentrations.

• Adjust antibody concentration: Titrate the antibody to find optimal signal-to-noise ratio.

• Increase washing stringency: Use higher salt concentrations or add mild detergents to washing buffers.

Advanced approaches:

• Antibody pre-absorption: Incubate antibody with lysates from knockout cells to remove cross-reactive antibodies.

• Peptide competition: Perform parallel experiments with antibody pre-incubated with immunizing peptide.

• Immunodepletion: Sequentially deplete the antibody with potential cross-reactive proteins.

Application-specific considerations:

• For immunohistochemistry, include antigen retrieval optimization.

• For immunoprecipitation, consider using more stringent washing conditions.

• For immunofluorescence, optimize fixation methods as different protocols can affect epitope accessibility and cross-reactivity patterns .

• What are the most effective methods for using ERG7 antibodies to investigate drug mechanisms targeting the ergosterol pathway?

ERG7 antibodies can be powerful tools for investigating drug mechanisms that target the ergosterol biosynthetic pathway:

Protein expression analysis:

• Treat cells with drugs (e.g., antifungals) at various concentrations and time points.

• Quantify ERG7 protein levels by immunoblotting to determine if the drug affects protein stability or expression.

• Compare effects on ERG7 with other pathway enzymes to assess pathway-specific responses.

Subcellular localization studies:

• Use immunofluorescence to determine if drug treatment alters ERG7 localization.

• Co-stain with markers for lipid particles, ER, and other relevant organelles.

• Quantify co-localization coefficients before and after drug treatment.

Protein-protein interaction analysis:

• Perform co-immunoprecipitation of ERG7 with ERG27 and other pathway proteins after drug treatment.

• Determine if the drug disrupts essential protein-protein interactions.

• Complement with proximity ligation assays for in situ interaction assessment.

Enzyme activity correlation:

• Measure lanosterol synthase activity in cell extracts after drug treatment.

• Correlate enzyme activity with protein levels detected by antibodies.

• Determine if post-translational modifications affect activity by combining immunoprecipitation with activity assays.

Research findings indicate that mutations in ERG7 (lanosterol synthase) and other ergosterol pathway genes can confer resistance to antifungal drugs . Using antibodies to monitor changes in protein expression, localization, and interactions in response to drug treatment can provide insights into both drug mechanism of action and resistance mechanisms.

• How can I develop antibodies specific to different functional states or conformations of ERG7?

Developing conformation-specific antibodies for ERG7 requires specialized approaches:

Strategic immunization protocols:

• Design peptides or protein fragments that represent specific conformational states of ERG7.

• For active-site specific antibodies, consider using mechanism-based inhibitors to stabilize transition states.

• Use structural data to identify regions that differ between conformational states.

Phage display selection strategy:

• Implement a dual-selection approach using phage-displayed antibody libraries .

• Perform positive selection against ERG7 in the desired conformation.

• Include negative selection steps against ERG7 in alternative conformations.

• Use computational modeling to identify different binding modes associated with specific conformations .

Yeast surface display screening:

• Express antibody fragments on yeast cell surface .

• Use fluorescence-activated cell sorting to isolate binders with desired specificity.

• Apply differential labeling to identify conformation-specific binders.

Validation approaches:

• Compare antibody binding under conditions that favor different ERG7 conformations.

• Use mutant ERG7 proteins locked in specific conformations as test antigens.

• Combine with functional assays to confirm state-specific recognition.

Recent advances in antibody engineering allow the design of antibodies with customized specificity profiles, either with high affinity for particular conformational states or with cross-specificity for multiple states . These approaches typically combine large-scale selection experiments, high-throughput sequencing, and machine learning techniques to identify different binding modes associated with specific conformational states .

• What controls should be included when using ERG7 antibodies in various experimental applications?

Proper controls are essential for ensuring reliable results with ERG7 antibodies across different applications:

Additional considerations:

• For all applications, include positive controls using samples known to express ERG7.

• When studying drug effects, include vehicle controls to account for solvent effects.

• For time course experiments, include time-matched controls.

• When comparing across cell types or tissues, normalize to appropriate reference genes or proteins specific to each sample type.